Autologous bone marrow stem cell therapy for the ischemic myocardium during coronary artery bypass grafting

Area of Science:

• Regenerative Medicine
• Cardiology
• Stem Cell Biology

Background:

• Cardiovascular diseases are a leading global cause of death.
• Ischemic heart disease treatment remains challenging despite medical and surgical advancements.
• Regenerative medicine, particularly cell-based therapies, offers a promising avenue for treating ischemic heart conditions.

Purpose of the Study:

• To evaluate the long-term safety of bone marrow-derived CD133(+) stem cell transplantation.
• To assess the efficacy of this therapy when combined with coronary artery bypass surgery.
• To provide a comprehensive overview of current knowledge on cell-based treatments for ischemic heart disease.

Main Methods:

• Review of long-term clinical experience with bone marrow-derived CD133(+) stem cell transplantation.
• Concomitant administration of stem cell therapy with coronary artery bypass surgery.
• Analysis of safety and efficacy data from experimental and clinical studies.

Main Results:

• Stem cell transplantation, particularly using CD133(+) cells from bone marrow, has demonstrated improvements in cardiac function.
• Combined therapy of stem cell transplantation and coronary artery bypass surgery shows potential for managing ischemic heart disease.
• Long-term safety data indicates a favorable profile for this regenerative approach.

Conclusions:

• Cell-based treatment, specifically using bone marrow-derived CD133(+) stem cells, is a viable and safe option for ischemic heart disease.
• This approach holds significant potential for improving cardiac function and patient outcomes.
• Further research and clinical application of stem cell therapy are warranted for cardiovascular regeneration.